Global Health Intrinsic Value
Global Health intrinsic value. Global Health (MEDANTA) median intrinsic value is ₹1475.56 from 10 valuation models (range ₹443–₹2919), vs current price ₹1478.30 — -0.2% downside (Trading Near Calculated Value), margin of safety -0.2%. Browse MEDANTA balance sheet details for revenue, profit, balance sheet and cash flow data.
MEDANTA Valuation Methods Summary — DCF, Graham Number & P/E
Global Health intrinsic value across 10 models vs current price ₹1478.30 — upside/downside and value range per method. For current market price and key ratios, visit Global Health share price today.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹722.48 | ₹577.98 - ₹866.98 | -51.1% | EPS: ₹32.84, Sector P/E: 22x |
| Book Value Method | asset | ₹1475.56 | ₹1328.00 - ₹1623.12 | -0.2% | Book Value/Share: ₹737.78, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹2211.85 | ₹1990.66 - ₹2433.04 | +49.6% | Revenue/Share: ₹1105.93, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹2918.52 | ₹2626.67 - ₹3210.37 | +97.4% | EBITDA: ₹1576.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹1796.02 | ₹1436.82 - ₹2155.22 | +21.5% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹443.49 | ₹399.14 - ₹487.84 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹507.38 | ₹456.64 - ₹558.12 | -65.7% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹2595.56 | ₹2336.00 - ₹2855.12 | +75.6% | ROE: 22.0%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹738.34 | ₹664.51 - ₹812.17 | -50.1% | EPS: ₹32.84, BVPS: ₹737.78 |
| Dividend Yield Method | dividend | ₹443.49 | ₹399.14 - ₹487.84 | -70.0% | DPS: ₹0.50, Target Yield: 2.5% |
MEDANTA Intrinsic Value vs Market Price — All Valuation Models
Global Health fair value range ₹443–₹2919 vs current market price ₹1478.30 across 10 valuation models. Analyse MEDANTA shareholding pattern to track promoter, FII and institutional holdings.
MEDANTA Intrinsic Value Analysis — Undervalued or Overvalued?
Global Health median intrinsic value ₹1475.56, current price ₹1478.30 — Trading Near Calculated Value by 0.2%, margin of safety -0.2%.
What is the intrinsic value of MEDANTA?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Global Health (MEDANTA) is ₹1475.56 (median value). With the current market price of ₹1478.30, this represents a -0.2% variance from our estimated fair value.
The valuation range spans from ₹443.49 to ₹2918.52, indicating ₹443.49 - ₹2918.52.
Is MEDANTA undervalued or overvalued?
Based on our multi-method analysis, Global Health (MEDANTA) appears to be trading near calculated value by approximately 0.2%.
MEDANTA Financial Health — Key Ratios vs Industry Benchmarks
Global Health financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 22.0% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 25.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.01x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
MEDANTA Cash Flow Quality — Operating & Free Cash Flow
Global Health operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹714 Cr | ₹170 Cr | Positive Free Cash Flow | 7/10 |
| March 2025 | ₹624 Cr | ₹264 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹612 Cr | ₹392 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹645 Cr | ₹474 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹311 Cr | ₹101 Cr | Positive Free Cash Flow | 7/10 |